AtriCure (NASDAQ:ATRC) Sets New 52-Week High – Here’s What Happened

AtriCure, Inc. (NASDAQ:ATRC)’s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as $55.72 and last traded at $52.3660, with a volume of 238397 shares traded. The stock had previously closed at $51.52.

Analysts Set New Price Targets

Several research firms have issued reports on ATRC. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. UBS Group lowered their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Piper Sandler lifted their price target on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Finally, Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and an average target price of $52.00.

AtriCure Stock Up 1.2%

The company has a 50 day moving average price of $40.56 and a 200-day moving average price of $32.96. The stock has a market capitalization of $2.65 billion, a PE ratio of 249.49 and a beta of 1.26. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period in the previous year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Karen Prange sold 3,564 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. This represents a 13.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Justin J. Noznesky sold 6,182 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the transaction, the insider owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. The trade was a 5.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 61,379 shares of company stock valued at $2,557,552 over the last ninety days. 4.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On AtriCure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. bought a new position in shares of AtriCure in the 2nd quarter worth about $37,000. Harbor Investment Advisory LLC bought a new stake in AtriCure during the second quarter worth about $40,000. Allworth Financial LP bought a new stake in AtriCure during the second quarter worth about $43,000. Smartleaf Asset Management LLC grew its holdings in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the period. Finally, Fifth Third Bancorp bought a new position in shares of AtriCure during the first quarter valued at approximately $51,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.